DRG 016
Medical DRGAutologous Bone Marrow Transplant with CC/MCC
What is MS-DRG 016?
MS-DRG 016 is a Medical Medicare Severity Diagnosis Related Group with a Complication or Comorbidity (CC). For FY 2026 it carries a relative weight of 5.9297 with a geometric mean length of stay of 16.1 days and an arithmetic mean of 17.2 days. Hospitals use this grouping to determine reimbursement for inpatient stays under Medicare.
FY 2026 Payment Data
Official values from Table 5 of the FY 2026 IPPS Final Rule (CMS).
Related MS-DRGs in This Severity Group
The same clinical condition is split into separate DRGs by complication severity. MCC pays more than CC, which pays more than no CC/MCC.
| DRG | Title | Rel. Weight | GMLOS |
|---|---|---|---|
| 016 | Autologous Bone Marrow Transplant with CC/MCCThis page | 5.9297 | 16.1 days |
| 017 | Autologous Bone Marrow Transplant without CC/MCC | 5.4323 | 8.3 days |
Linked ICD-10-PCS Procedure Mappings
- 30233C0
Transfusion of Autologous Hematopoietic Stem/Progenitor Cells, Genetically Modified into Peripheral Vein, Percutaneous Approach
BillableSection 3 - 30233G0
Transfusion of Autologous Bone Marrow into Peripheral Vein, Percutaneous Approach
BillableSection 3 - 30233X0
Transfusion of Autologous Cord Blood Stem Cells into Peripheral Vein, Percutaneous Approach
BillableSection 3 - 30233Y0
Transfusion of Autologous Hematopoietic Stem Cells into Peripheral Vein, Percutaneous Approach
BillableSection 3 - 30243C0
Transfusion of Autologous Hematopoietic Stem/Progenitor Cells, Genetically Modified into Central Vein, Percutaneous Approach
BillableSection 3 - 30243G0
Transfusion of Autologous Bone Marrow into Central Vein, Percutaneous Approach
BillableSection 3 - 30243X0
Transfusion of Autologous Cord Blood Stem Cells into Central Vein, Percutaneous Approach
BillableSection 3 - 30243Y0
Transfusion of Autologous Hematopoietic Stem Cells into Central Vein, Percutaneous Approach
BillableSection 3 - XW1337A
Transfusion of Marnetegragene Autotemcel into Peripheral Vein, Percutaneous Approach, New Technology Group 10
BillableSection X - XW133B8
Transfusion of Betibeglogene Autotemcel into Peripheral Vein, Percutaneous Approach, New Technology Group 8
BillableSection X - XW133F8
Transfusion of OTL-103 into Peripheral Vein, Percutaneous Approach, New Technology Group 8
BillableSection X - XW133G8
Transfusion of Atidarsagene Autotemcel into Peripheral Vein, Percutaneous Approach, New Technology Group 8
BillableSection X - XW133H9
Transfusion of Lovotibeglogene Autotemcel into Peripheral Vein, Percutaneous Approach, New Technology Group 9
BillableSection X - XW133J8
Transfusion of Exagamglogene Autotemcel into Peripheral Vein, Percutaneous Approach, New Technology Group 8
BillableSection X - XW133SB
Transfusion of Mozafancogene Autotemcel into Peripheral Vein, Percutaneous Approach, New Technology Group 11
BillableSection X - XW1437A
Transfusion of Marnetegragene Autotemcel into Central Vein, Percutaneous Approach, New Technology Group 10
BillableSection X - XW143B8
Transfusion of Betibeglogene Autotemcel into Central Vein, Percutaneous Approach, New Technology Group 8
BillableSection X - XW143F8
Transfusion of OTL-103 into Central Vein, Percutaneous Approach, New Technology Group 8
BillableSection X - XW143G8
Transfusion of Atidarsagene Autotemcel into Central Vein, Percutaneous Approach, New Technology Group 8
BillableSection X - XW143H9
Transfusion of Lovotibeglogene Autotemcel into Central Vein, Percutaneous Approach, New Technology Group 9
BillableSection X - XW143J8
Transfusion of Exagamglogene Autotemcel into Central Vein, Percutaneous Approach, New Technology Group 8
BillableSection X - XW143SB
Transfusion of Mozafancogene Autotemcel into Central Vein, Percutaneous Approach, New Technology Group 11
BillableSection X
